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Objectives This study evaluated the predictive factors and prognostic value of new-onset persistent left bundle branch block
(LBBB) in patients undergoing transcatheter aortic valve implantation (TAVI) with a balloon-expandable valve.
Background The predictors of persistent (vs. transient or absent) LBBB after TAVI with a balloon-expandable valve and its clin-
ical consequences are unknown.
Methods A total of 202 consecutive patients with no baseline ventricular conduction disturbances or previous permanent
pacemaker implantation (PPI) who underwent TAVI with a balloon-expandable valve were included. Patients
were on continuous electrocardiographic (ECG) monitoring during hospitalization and 12-lead ECG was per-
formed daily until hospital discharge. No patient was lost at a median follow-up of 12 (range: 6 to 24) months,
and ECG tracing was available in 97% of patients. The criteria for PPI were limited to the occurrence of high-
degree atrioventricular block (AVB) or severe symptomatic bradycardia.
Results New-onset LBBB was observed in 61 patients (30.2%) after TAVI, and had resolved in 37.7% and 57.3% at hos-
pital discharge and 6- to 12-month follow-up, respectively. Baseline QRS duration (p  0.037) and ventricular
depth of the prosthesis (p  0.017) were independent predictors of persistent LBBB. Persistent LBBB at hospital
discharge was associated with a decrease in left ventricular ejection fraction (p  0.001) and poorer functional
status (p  0.034) at 1-year follow-up. Patients with persistent LBBB and no PPI at hospital discharge had a
higher incidence of syncope (16.0% vs. 0.7%; p  0.001) and complete AVB requiring PPI (20.0% vs. 0.7%;
p  0.001), but not of global mortality or cardiac mortality during the follow-up period (all, p  0.20). New-onset
LBBB was the only factor associated with PPI following TAVI (p  0.001).
Conclusions Up to 30% of patients with no prior conduction disturbances developed new LBBB following TAVI with a balloon-
expandable valve, although it was transient in more than one third. Longer baseline QRS duration and a more
ventricular positioning of the prosthesis were associated with a higher rate of persistent LBBB, which in turn de-
termined higher risks for complete AVB and PPI, but not mortality, at 1-year follow-up. (J Am Coll Cardiol
2012;60:1743–52) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.07.035New-onset left bundle branch block (LBBB) is the most
frequent conduction alteration associated with transcatheter
aortic valve implantation (TAVI) (1–10). Several studies
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apolis, Minnesota) (1,2,4–6,8).
Furthermore, all studies to date
have included patients with con-
duction disturbances prior to
TAVI (including patients with
prior pacemaker in some), which
may indeed lead to a more diffi-
cult interpretation of the exact
role of TAVI on the develop-
ment of new conduction distur-
bances and its predictors.
See page 1753
Importantly, while it has been shown that the vast majority
of conduction disturbances occur during the TAVI proce-
dure, a significant number resolve within the first days
following the procedure, especially with the use of a
balloon-expandable valve (9,10). However, no data exist on
the factors associated with persistent (vs. transient) new-
onset LBBB following TAVI and its clinical consequences.
It is therefore unknown whether patients leaving the hos-
pital with a new-onset LBBB following TAVI have a higher
risk for clinical events, particularly new-onset complete
atrioventricular block (AVB) and/or sudden death. The
objectives of this study were therefore to: 1) determine the
incidence and predictors of new-onset persistent LBBB in
patients without baseline intraventricular conduction abnor-
malities undergoing TAVI with a balloon-expandable valve;
and 2) evaluate the long-term prognostic significance of
persistent LBBB in this population.
Methods
Study population. Of 348 consecutive patients (Quebec
Heart & Lung Institute: n  263; Vall d’Hebron hospital:
n  85), who underwent TAVI with a balloon-expandable
valve (Sapien or Sapien XT, Edwards Lifesciences, Irvine
LLC, California); 146 patients were excluded because of the
following reasons: prior pacemaker (n  57), prior intra-
ventricular conduction abnormalities (complete or incom-
plete right or left bundle branch block, n  83), death, or
conversion to open heart surgery before the first ECG
(4 and 2 patients, respectively). The final study population
consisted of 202 patients. Details about the TAVI proce-
dure have been previously reported (11). All baseline,
procedural, and post-operative data were prospectively re-
corded. Periprocedural complications were defined accord-
ing to the Valve Academic Research Consortium criteria
(12). The degree of native aortic valve calcification was
measured (in Agatston units) in all patients who had
noncontrast ECG-gated computed tomography prior to the
procedure (n  131; 65%). Patients underwent transtho-
racic echocardiography at baseline, at hospital discharge,
Abbreviations
and Acronyms
AVB  atrioventricular
block
ECG  electrocardiography
LBBB  left bundle branch
block
LVEF  left ventricular
ejection fraction
PPI  permanent
pacemaker implantation
TAVI  transcatheter aortic
valve implantationand at 6- to 12-month follow-up. The position of the
e
ftranscatheter valve after implantation was evaluated by
transesophageal echocardiography (long-axis view) as pre-
viously described (9).
ECG data and criteria for pacemaker implantation.
ECG tracings were recorded at baseline (within 24 h prior
to the procedure), immediately after the procedure, and
then every 24 h until hospital discharge. Furthermore,
patients were on continuous ECG monitoring during the
entire hospitalization period following the procedure. All
ECG tracings were analyzed by a cardiologist blinded to the
clinical data. The diagnosis of intraventricular conduction
abnormalities was based on recommendations from the Amer-
Baseline and Procedural Characteristicsof the Study Population (n  202)Table 1 Baseline and Procedu al Characteristicsof the Study Population (n  202)
Baseline characteristics
Age (yrs) 80 8
Female 121 (59.9)
Body mass index (kg/m2) 27 5
Comorbidities
Hypertension 178 (88.1)
Diabetes mellitus 67 (33.2)
COPD 50 (24.8)
CAD 118 (58.4)
eGFR (ml/min) 56.8 23.0
Baseline treatment
Beta-blockers 94 (46.5)
Calcium channel blockers 58 (28.7)
Amiodarone 13 (6.4)
STS-PROM score (%) 7.5 3.7
ECG (ms)
PR interval 174 38
QRS duration 92 10
Echocardiography
LVEF (%) 57 12
Mean gradient (mm Hg) 47 18
Aortic valve area (cm2) 0.64 0.22
Computed tomography
Aortic valve calcification (Agatston units) 3227 2121
Procedural variables
Success 190 (94.1)
Approach, n (%)
Transapical 117 (57.9)
Transfemoral 85 (42.1)
Ratio valve prosthesis size/aortic annulus 1.17 0.07
Prosthesis ventricular depth* (mm) 1.87 2.62
In-hospital outcomes
Death 14 (6.9)
Stroke 4 (2.0)
Myocardial infarction 2 (1.0)
Major bleeding 23 (11.4)
Major vascular complications 7 (3.5)
Pacemaker implantation 14 (6.9)
Length of stay (days) 7 (5–10)
Values are mean  SD, n (%), or median (interquartile range). *Distance between the hinge point
of the mitral valve and the ventricular end of the valve prosthesis frame (transesophageal
echocardiography [TEE], long-axis view).
CAD  coronary artery disease; COPD  chronic obstructive pulmonary disease; ECG 
lectrocardiography; eGFR  estimated glomerular filtration ratio; LVEF  left ventricular ejection
raction; STS-PROM  Society of Thoracic Surgeons predicted risk of mortality.
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dation/Heart Rhythm Society (AHA/ACCF/HRS) for the stan-
dardization and interpretation of ECGs (13). The policies for
permanent pacemaker implantation (PPI) were in accordance
with the ACC/AHA/HRS guidelines for device-based therapy
of cardiac rhythm abnormalities (14).
Transient LBBB was defined as the occurrence of new
BBB that resolved before hospital discharge. Persistent LBBB
as defined as any new-onset LBBB that persisted at hospital
ischarge. Those patients who developed LBBB after the
rocedure and required a PPI or died before hospital discharge
without proven resolution of the LBBB) were also included in
he group of patients with persistent LBBB.
ollow-up. Follow-up was carried out by clinical visits or
hone contact at 30 days, 6 months, 1 year, and yearly
hereafter. The minimum follow-up for the study popula-
ion was 6 months (median [range]: 12 [6 to 24] months),
nd no patient was lost to follow-up. An ECG tracing was
btained at 6- to 12-month follow-up in 97% of survivors at
hat time point.
tatistical analysis. Categorical variables were compared
sing the chi-square or Fisher exact test as appropriate.
ontinuous variables were compared using the t or Wil-
coxon rank sum test and 1-way analysis of variance if
comparisons involved 2 groups. A repeated-measures
model with interaction was used to compare the changes
Figure 1 Conduction Abnormalities Following TAVI
Flowchart showing the occurrence of intraventricular conduction abnormalities imm
period and up to 6- to 12-month follow-up. CAVB  complete atrioventricular block
conduction disturbances; LAHB  left anterior hemiblock; LBBB  left bundle branin left ventricular ejection fraction (LVEF) at different
time points between groups (persistent LBBB vs. absent
or transient LBBB). Post-hoc comparisons were per-
formed using the Tukey test. The predictors of new-
onset, persistent LBBB (vs. absent or transient LBBB)
were determined using a binary logistic regression model
that included variables with a p value 0.10 on univariate
analysis. Age, baseline QRS duration, and ventricular
depth of the prosthesis were the variables included in the
analysis. The predictors of significant LVEF changes
over time were determined using a multivariate regression
linear model that included variables with a p value 0.10
on univariate analysis. Hypertension, new-onset persis-
tent LBBB and peak troponin T were the variables
included in the analysis. Cumulative outcomes at 1-year
follow-up were assessed by Kaplan-Meier estimates and
compared using the log-rank test. A 30-day landmark
analysis was also performed. The results were considered
significant with p values 0.05. All analyses were con-
ducted using the statistical package SAS version 9.2 (SAS
Institute Inc., Cary, North Carolina).
Results
The baseline and procedural characteristics of the study
population are shown in Table 1.
ly following transcatheter aortic valve implantation, during the hospitalization
B  incomplete left bundle branch block; IVCD  nonspecific intraventricular
ck; TAVI  transcatheter aortic valve implantation.ediate
; ILBB
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TAVI and Persistent LBBB October 30, 2012:1743–52New-onset conduction disturbances and LBBB following
TAVI. New-onset LBBB and overall conduction distur-
bances following TAVI are shown in Figure 1. New-onset,
complete LBBB was observed in 57 patients (28.2%) on the
first ECG following the procedure, and an additional 4
patients developed new-onset LBBB at a mean of 24 17 h
(range: 12 to 48 h) following TAVI, leading to a global
incidence of new-onset LBBB during the hospitalization
period of 30.2%. The ECG performed at hospital discharge
showed the persistence and resolution of LBBB in 25 and
23 patients, respectively.
At 6- to 12-month follow-up, no conduction disorders
were observed in 65% of survivors at that time point. In
patients with persistent LBBB at hospital discharge (n25),
LBBB had resolved in 12 patients (48%), 4 patients required
PPI because of third-degree AVB (16%), and LBBB per-
sisted in 9 patients (36%). No new-onset LBBB was
documented in any patient after hospital discharge. The
mean changes in QRS duration throughout the study period
are shown in Figure 2.
Predictive factors of new-onset, persistent LBBB. Base-
line and procedural characteristics of the patients, grouped
according to the occurrence of persistent LBBB (vs. tran-
sient or no LBBB) following the TAVI procedure are
shown in Table 2. Factors associated with persistent LBBB
(vs. no or transient LBBB) in the univariate analysis were
ventricular depth of the prosthesis (3.04 1.72 mm vs. 1.56
2.73 mm; p 0.009), longer baseline QRS duration (96 10
s vs. 91 11 ms; p 0.005) and younger age (77 9 years
s. 80  7 years; p  0.010). In the multivariate analysis,
rosthesis ventricular depth (odds ratio [OR]: 1.37 for each
ncrease of 1 mm; 95% confidence interval [CI]: 1.06 to
.77; p  0.017), and baseline QRS duration (OR: 1.24 for
ach increase of 4 ms; 95% CI: 1.01 to 1.51; p  0.037)
ere independent predictors of persistent LBBB. No pre-
ictors of transient LBBB were identified.
rognostic value of new-onset, persistent LBBB. Clini-
al outcomes during the hospitalization period according to
he occurrence of new-onset LBBB are shown in Table 3.
t a median (range) follow-up of 12 (6 to 24) months, a
otal of 32 patients had died, with no differences between
atients with and without persistent LBBB. There was 1
ase of sudden death during the follow-up period, which
ccurred 9 months after TAVI in a patient with no LBBB
t hospital discharge. Survival curves at 1-year follow-up are
hown in Figures 3A and 3B. The overall rate of PPI was
igher in patients with persistent LBBB compared to the
est of the study population (34.2 vs. 4.3%; p  0.001).
reedom from PPI curves up to 1-year follow-up are shown
n Figure 3C. Thirty-day landmark analyses for cumulative
utcomes are shown in Figures 3D to 3F. Baseline and
rocedural characteristics of the patients grouped according
o the need for PPI are shown in Table 4. The occurrence
f new-onset LBBB following the procedure (hazard ratio:
.99; 95% CI: 2.93 to 15.61; p  0.001) was the only factor
ssociated with PPI during the entire study period. pLate Clinical outcomes of the 25 patients with persistent
BBB and no PPI at hospital discharge are detailed in
able 5. None of these patients had sudden death at a
edian of 12 (6 to 24) months. However, the rates of
yncope and the need for PPI during the follow-up period
ere higher in this group than in the rest of the study
opulation (syncope: 16.0% vs. 0.7% [p  0.001]; PPI:
0.0% vs. 0.7%, p  0.001). The individual characteristics
f the patients requiring PPI during the follow-up period
re shown in Table 6. At 1-year follow-up, patients with
ersistent LBBB had a poorer New York Heart Association
unctional class compared to patients with no or transient
BBB (p  0.034) (Fig. 4).
chocardiographic data. Valve hemodynamics of the pa-
ients with and without new-onset LBBB are shown in
igure 5. The changes in LVEF throughout the study
Figure 2 Changes in QRS Width Following TAVI
Changes in mean QRS duration following transcatheter aortic valve implanta-
tion and up to 6- to 12-month follow-up in overall population (A) and according
to the occurrence of new-onset left bundle branch block (B). Error bars indicate
standard errors. *Different from the No LBBB group, p  0.05; †different from
the Transient LBBB group, p  0.0001. Abbreviation as in Figure 1.eriod are shown in Figure 6. Patients with persistent
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October 30, 2012:1743–52 TAVI and Persistent LBBBLBBB at hospital discharge exhibited a decrease in LVEF
of 4.75 8.02% (95% CI: 0.99 to 8.50; p 0.031) at 1-year
ollow-up, whereas patients with no/transient LBBB had an
ncrease in LVEF of 2.52  11.32% (95% CI: 0.27 to 4.77;
 0.0014 [p  0.0012 between groups]). The LVEF at
Baseline and Procedural Findings, Accordingto the Occurrence of New-Onset LBBB FollowingTable 2 Baseline and Procedural Fin s, Ato the Occurrence of New-Onset LB
No LBB
(n  14
Baseline characteristics
Age (yrs) 81 8
Female 83 (58.9)
Body mass index (kg/m2) 26 5
Comorbidities
Hypertension 119 (84.4)
Diabetes mellitus 44 (31.2)
COPD 35 (24.8)
CAD 79 (56.0)
eGFR (ml/min) 56.6 2
Baseline treatment
Beta-blockers 64 (45.4)
Calcium channel blockers 38 (27.0)
Amiodarone 8 (5.7)
STS-PROM score (%) 7.6 3
ECG (ms)
PR interval 176 3
QRS duration 90 1
Echocardiography
LVEF (%) 57 1
Mean gradient (mm Hg) 46 1
Aortic valve area (cm2) 0.65 0
Computed tomography
Aortic valve calcification (Agatston units) 2,544 (1,600
Procedural variables
Approach
Transapical 79 (56.0)
Transfemoral 62 (44.0)
Ratio aortic prosthesis size/aortic annulus 1.16 0
Prosthesis ventricular depth‡ (mm) 1.64 2
Values are mean  SD, n (%), or median (interquartile range). *One
categorical variables. †p  0.05 versus no LBBB by Tukey post-hoc te
end of the valve prosthesis frame (TEE, long-axis view). §p  0.05 ve
Abbreviations as in Table 1.
In-Hospital Outcomes, Accordingto the Occurrence of New-Onset LBBBTable 3 In-H spital Outcomes, Accordingto the Occurrence of New-Onset LBBB
Variable
New-Onset LBBB
(n  61)
No LBBB
(n  142) p Value
Complete AVB 8 (13.1) 6 (4.3) 0.023
Need for PPI 8 (13.1) 6 (4.3) 0.023
Major vascular complications 4 (6.6) 3 (2.1) 0.202
Major bleeding 9 (14.8) 14 (9.9) 0.194
Myocardial infarction 0 2 (1.4) 0.998
Stroke 3 (4.9) 1 (0.7) 0.083
Death 6 (9.8) 8 (5.7) 0.285
Hospital length of stay (days) 8 (5–13) 7 (6–9) 0.091Values are n (%) or median (interquartile range).
AVB  atrioventricular block; other abbreviations as in Table 1.-year follow-up was lower in the persistent LBBB group
ompared to the no/transient LBBB group (53  13% vs.
2  9%; p  0.0014). The changes in LVEF over time
epending on baseline and procedural variables are shown in
able 7. In the multivariate linear regression analysis, the
ccurrence of persistent LBBB was the only independent
redictive factor of decreased LVEF at 1-year follow-up (point
stimate  standard error: –8.6  2.6; R2: 0.14; p  0.001).
Discussion
New-onset LBBB has been reported in 29% to 65% of the
patients following TAVI with a self-expandable valve (1–8),
and in 12% to 18% following TAVI with a balloon-
expandable valve (3,7,9,10). The rate of 30% of new-onset
LBBB observed in the present study might have been
related mainly to the exclusion of patients with conduction
abnormalities (including LBBB) or pacemaker prior to
TAVI. In fact, the rate of new-onset LBBB in previous
Iding
ollowing TAVI
Transient LBBB
(n  23)
Persistent LBBB
(n  38) p Value*
79 6 77 9† 0.019
17 (73.9) 21 (55.3) 0.328
26 5 28 6 0.125
22 (95.7) 37 (97.4) 0.041
8 (34.8) 15 (39.5) 0.615
3 (13.0) 12 (31.6) 0.261
17 (73.9) 22 (57.9) 0.277
54.6 20.4 59.1 26.3 0.742
14 (60.9) 16 (42.1) 0.332
8 (34.8) 12 (31.6) 0.648
2 (8.7) 3 (7.9) 0.729
6.1 3.7 7.4 3.4 0.476
158 23 174 45 0.114
92 9 96 10† 0.033
54 15 58 11 0.440
47 19 49 19 0.696
0.63 0.28 0.61 0.17 0.547
2) 2,045 (1,666–4,209) 3,150 (1,944–5,358) 0.412
0.335
12 (52.2) 26 (68.4)
11 (47.8) 12 (31.6)
1.18 0.09 1.18 0.07 0.097
1.22 2.23 3.04 1.72†§ 0.028
alysis of variance for continuous variables and Fisher exact test for
tance between the hinge point of the mitral valve and the ventricular
nsient LBBB by Tukey post-hoc test.TAVccor
BB F
B
1)
2.5
.8
6
0
2
7
.22
–4,44
.07
.85
-way an
st. ‡Disstudies would have increased up to 75% and 30% for
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if patients with complete bundle branch block and/or
pacemaker had been excluded (1–6,8–10). Importantly, and
in accordance with prior studies using balloon-expandable
Figure 3 Survival Curves and Landmark Analysis Survival Curve
in Patients With and Without Persistent LBBB Follow
Kaplan-Meier curves up to 1-year follow-up for (A) overall mortality, (B) cardiac mo
onset persistent LBBB following transcatheter aortic valve implantation. Kaplan-Me
(E) cardiac mortality, and (F) permanent pacemaker implantation (PPI) in patientsvalves, a significant number of these conduction abnormal-ities resolved within the first few days following the inter-
vention (9,10). In a further step, this study also shows that
up to about one-half of the cases of new-onset LBBB
present at hospital discharge (median: 7 days after TAVI)
30-Day Follow-Up
AVI
and (C) permanent pacemaker implantation in patients with and without new-
rves from 30 days following TAVI to 12 months for (D) overall mortality,
nd without persistent LBBB. Abbreviations as in Figure 1.s at
ing T
rtality,
ier cu
with ahad resolved at 1-year follow-up. This finding clearly differs
ratio; o
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October 30, 2012:1743–52 TAVI and Persistent LBBBfrom the experience with the self-expandable valve system,
in which LBBB persisted in the vast majority of patients up
to 6-month follow-up (15). Nuis et al. (8) showed that
about 50% of conduction disturbances occurring during the
TAVI procedure took place before valve implantation and
Baseline and Procedural Findings, According to(In-Hospit l or During the Follow-Up Period)Table 4 Baseli e and Procedural Fin s, A(In-Hospital or During the Follow-Up
PPI
(
Clinical characteristics
Age (yrs)
Female 1
Body mass index (kg/m2)
Comorbidities
Hypertension 1
Diabetes mellitus
COPD
CAD 1
eGFR (ml/min) 51
Baseline treatment
Beta-blockers
Calcium channel blockers
Amiodarone
STS-PROM score 6
ECG (ms)
PR interval 1
QRS duration
Echocardiography
LVEF (%)
Mean gradient (mm Hg)
Aortic valve area (cm2) 0.
Computed tomography
Aortic valve calcification (Agatston units) 3,3
Procedural variables
Approach
Transapical 1
Transfemoral
Ratio prosthesis/aortic annulus 1.
Ventricular depth of prosthesis* (mm) 3.
Residual AR 2
New-onset LBBB 1
Values are mean  SD or n (%). *Distance between the hinge point o
long-axis view).
AR  aortic regurgitation; CI  confidence interval; HR  hazard
Late Clinic Outcomes, According to the PresencPersistent LBBB (With No Pacemaker ImplantatTable 5 Late Clinic Outcomes, According toPersistent LBBB (With No Pacemak
Outcome
Overall
(n  176)
Follow-up (months)* 12 (6–24)
Syncope 5 (2.8)
Heart failure requiring hospitalization 26 (14.8)
PPI 6 (3.4)
Death
Overall 32 (18.2)
Cardiac death 14 (8.0)
Sudden death 1 (0.6)Values are median (interquartile range) or n (%). *Median (IQR).
Abbreviations as in Table 1.were related to wire manipulation or balloon valvuloplasty.
It is therefore not surprising that in the absence of perma-
nent damage or mechanical stress of the left bundle branch,
a significant number of these conduction disturbances re-
solve within the few days following the procedure. Another
eed for PPIding t the Need for PPI
od)
lative)
0)
No PPI
(n  182) HR (95% CI) p Value
80 8 1.02 (0.96–1.09) 0.454
.0) 109 (59.9) 0.90 (0.37–2.22) 0.803
27 5 1.01 (0.92–1.11) 0.762
.0) 161 (88.5) 0.59 (0.17–2.04) 0.406
.0) 61 (33.5) 0.96 (0.37–2.51) 0.938
.0) 45 (24.7) 1.16 (0.42–3.22) 0.778
.0) 107 (58.8) 0.95 (0.39–2.30) 0.903
0.6 57.3 23.2 0.99 (0.97–1.01) 0.343
.0) 86 (47.3) 0.70 (0.28–1.72) 0.434
.0) 50 (27.5) 1.64 (0.67–4.01) 0.281
.0) 11 (6.0) 1.80 (0.41–7.81) 0.433
.8 7.6 3.8 0.94 (0.79–1.11) 0.457
9 172 35 1.01 (0.99–1.02) 0.354
0 92 10 1.02 (0.97–1.07) 0.500
57 12 1.03 (0.99–1.08) 0.137
1 47 17 0.99 (0.97–1.02) 0.491
.19 0.64 0.22 0.50 (0.40–6.26) 0.591
,345 3,209 2,104 — 0.854
1.66 (0.63–4.33) 0.303
.0) 103 (56.6) — —
.0) 79 (43.4) — —
.09 1.16 0.07 — 0.407
.65 1.71 2.68 1.27 (0.96–1.68) 0.100
) 27 (14.8) 1.02 (0.79–1.31) 0.877
.0) 47 (25.8) 5.99 (2.29–15.61) 0.001
itral valve and the ventricular end of the valve prosthesis frame (TEE,
ther abbreviations as in Table 1.
New-Onset,at Hospital DischargePresence of New-Onset,
plantation) at Hospital Discharge
rsistent LBBB
(n  25)
No/Transient LBBB
(n  151) p Value
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7 (28.0) 19 (12.6) 0.124
5 (20.0) 1 (0.7) 0.001
4 (16.0) 28 (18.5) 0.998
1 (4.0) 13 (8.6) 0.696
0 1 (0.7) 0.999the Nccor
Peri
(Cumu
n  2
81 6
2 (60
27 6
7 (85
6 (30
5 (25
1 (55
.9 2
8 (40
8 (40
2 (10
.9 2
91 5
94 1
62 8
44 2
61 0
62 2
4 (70
6 (30
17 0
19 1
1 (5.0
4 (70
f the me ofion)the
er Im
Pe
1750 Urena et al. JACC Vol. 60, No. 18, 2012
TAVI and Persistent LBBB October 30, 2012:1743–52important finding of the present study is the fact that no
new intraventricular conduction disturbances were observed
either after day 2 in the periprocedural period or later during
the follow-up period.
Predictive factors of new-onset, persistent LBBB. Un-
like all prior studies evaluating the predictive factors of
LBBB (transient and persistent) following TAVI, this study
specifically focused in the prediction of persistent LBBB
compared with transient or absent LBBB. Of note, no
predictive factors were encountered for transient LBBB,
whereas both a lower (ventricular) valve positioning and
longer QRS duration were associated with persistent LBBB
following balloon-expandable valve implantation. A longer
QRS duration might be associated with an early stage of the
conduction system disease which, in turn, can increase the
vulnerability of this system to any trauma during the TAVI
procedure (16,17). A more ventricular positioning of the
valve prosthesis might increase the risk for mechanical stress
and direct damage of the conduction system, leading to a
higher risk for conduction disturbances. In accordance with
the results of this study, a lower positioning of the valve
prosthesis has been shown to be a predictor of conduction
disturbances and PPI in patients following TAVI with the
self-expandable device (1,6,7).
Figure 4 Changes in Functional Class Following TAVI
Changes in New York Heart Association functional class in patients with and
without persistent LBBB following TAVI. Abbreviations as in Figure 1.
Individual Characteristics of the PatientsRequiring PPI During he Follow-Up PeriodTable 6 Individual Charact ristics of the PaRequiring PPI During the Follow-Up
Age (yrs) STS-PROM (%) Persistent LBBB
69 6.8 Yes
70 5.2 Yes
76 3.5 No
77 4.5 Yes
78 7.9 Yes
79 10.8 Yes
Abbreviations as in Tables 1 and 3.Prognostic value of new-onset, persistent LBBB. This
study showed that the occurrence of new-onset, persistent
LBBB following TAVI is associated with a much higher
risk for complete AVB requiring PPI. It is of high clinical
relevance that the higher risk for complete AVB started very
soon (hours to days) after the appearance of LBBB, and
Figure 5 Valve Hemodynamics Following TAVI
(A) Changes in mean transvalvular gradient and aortic valve area, according to
the occurrence on new-onset LBBB. (B) Degree of residual aortic regurgitation,
according to the presence of new-onset LBBB. Abbreviations as in Figure 1.
d
ing of PPI (months) Reason for PPI
7 Complete AVB ( syncope)
4 Complete AVB ( heart failure)
19 Complete AVB ( pre-syncope)
1 Complete AVB ( syncope)
11 Complete AVB ( syncope)
43 Complete AVB ( syncope)tients
Perio
Tim
r
i
w
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October 30, 2012:1743–52 TAVI and Persistent LBBBcontinued during the follow-up period in those patients
with persistent LBBB. In fact, all but 1 case of complete
AVB leading to PPI during the follow-up period occurred
in patients with persistent LBBB, and syncope was the
clinical presentation in most patients. While we found no
relationship between the occurrence of LBBB and acute or
late mortality following TAVI, and no cases of sudden
death were reported among the patients with persistent
LBBB. The potential usefulness of a closer follow-up (serial
ECGs, 24- to 48-h ECG monitoring within the first
months following TAVI), and/or systematic electrophysi-
ologic studies in such cases should probably be investigated
in the future.
Patients with persistent LBBB had a significant impair-
ment in LVEF during the follow-up period and exhibited a
poorer functional status compared to those with no/
transient LBBB. Tzikas et al. (18) reported a lack of
post-procedural improvement in LVEF in patients with
new-onset conduction disturbances (LBBB and/or pace-
maker implantation) after self-expandable valve implanta-
tion. It is known that the presence of LBBB generates a
ventricular contraction asynchrony secondary to an abnor-
mal electrical activation, which in turn causes left ventricular
remodeling and further ventricular dysfunction (19). The
potential beneficial effects of resynchronization therapy (20)
might merit evaluation in future studies.
Study limitations. The results regarding the lack of a
elationship between persistent LBBB and cardiac mortal-
ty, and particularly sudden death, should be interpreted
Figure 6 Changes in Left Ventricular Ejection Fraction
Following TAVI
Changes in left ventricular ejection fraction following TAVI in patients with and
without persistent LBBB following TAVI. Abbreviations as in Figure 1.ith caution due to the relatively small sample size. TheseChanges in LVEF Between HospitalDischarge and 6- to 12-Month Follow-Up,According to Baseline and Procedural Variables
Table 7
Ch ng s in LVEF B ween Hospital
Discharge and 6- to 12-Month Follow-Up,
According to Baseline and Procedural Variables
 LVEF p Value
Clinical characteristics
Age 0.907
 Median (81 yrs) 1.18 9.42
 Median (81 yrs) 1.42 12.68
Sex 0.824
Male 1.64 9.14
Female 1.15 11.98
Comorbidities
Hypertension 0.035
Yes 0.56 11.10
No 7.46 9.80
Diabetes mellitus 0.104
Yes 0.26 10.53
No 3.94 12.34
COPD 0.202
Yes 2.04 10.57
No 1.00 12.71
CAD 0.385
Yes 2.50 14.06
No 0.51 8.70
Baseline eGFR 0.235
 Median (55 ml/min) 2.54 12.02
 Median (55 ml/min) 0.11 10.19
STS-PROM score (%) 0.655
 Median (7.20 %) 1.11 10.39
 Median (7.20%) 2.01 9.62
ECG
PR interval 0.974
 Median (168 ms) 2.07 9.27
 Median (168 ms) 2.14 11.92
QRS duration 0.645
 Median (92 ms) 0.80 10.86
 Median (92 ms) 1.75 11.46
Echocardiography
LVEF 0.420
 Median (60%) 0.63 9.79
 Median (60%) 2.51 13.27
Mean gradient 0.784
 Median (43 mm Hg) 1.03 11.57
 Median (43 mm Hg) 1.59 10.78
Aortic valve area 0.424
 Median (0.60 cm2) 0.95 8.18
 Median (0.60 cm2) 2.47 11.96
Procedural variables
Transcatheter approach 0.784
Transapical 1.10 10.70
Transfemoral 1.69 12.05
New-onset LBBB 0.001
No/Transient LBBB 2.52 11.32
Persistent LBBB 4.75 8.02
Residual aortic regurgitation 0.625
2 1.09 11.38
2 2.50 9.88
Peak CK-MB 0.446
 Median (19.30 g/dl) 0.95 10.95
 Median (19.30 g/dl) 2.59 7.73
Peak troponin T 0.092
 Median (0.50 g/dl) 0.20 9.64
 Median (0.50 g/dl) 3.97 9.91
Values are mean  SD.
CK-MB creatinine kinase–myocardial band; IVS interventricular septum; other definitions as
in Table 1.
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TAVI and Persistent LBBB October 30, 2012:1743–52results will therefore have to be confirmed in larger studies
in the future.
Conclusions
In patients with aortic stenosis and no prior conduction
abnormalities, new-onset LBBB occurred in up to 30% of
patients following TAVI with a balloon-expandable valve,
although this conduction disturbance was persistent in less
than half of patients at 6- to 12-month follow-up. The
ventricular depth of the prosthesis and QRS duration
predicted the occurrence of persistent LBBB, which was
associated with a higher rate of AVB and PPI, and poorer
functional status and ventricular function at midterm
follow-up. These results highlight the importance of close
monitoring and follow-up of patients with persistent LBBB
following TAVI and support the performance of larger
studies to further evaluate the prognostic value of these
conduction abnormalities following TAVI.
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